The failure of Novartis's antisense drug Pella Carson, contrasted with the potential success of Amgen's siRNA targeting the same pathway, could have a profound negative impact on the entire antisense field, favoring siRNA technology for large population diseases.
Even while its antisense drug Pella Carson was in a major Phase 3 trial, Novartis proactively licensed a competing siRNA technology for the same target. This suggests a sophisticated hedging strategy or internal doubts about the original drug's prospects, a move made years before the trial's failure.
Pharma's deal-making in the past year shows a renewed appetite for risk. Unlike the previous focus on validated targets during the bear market, companies are now investing heavily in disruptive, less-proven technologies like T-cell engagers for autoimmune disease, signaling a strategic pivot toward high-reward innovation.
While pharma companies are increasingly licensing assets from Chinese biotechs, they are not acquiring them. This dichotomy highlights how geopolitical tensions and logistical complexities are creating a ceiling on US-China biotech integration, limiting partnerships to licensing-in rather than full M&A.
Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.
The White House's Most Favored Nation (MFN) drug pricing deals are not as sweeping as portrayed. Companies are successfully negotiating significant carve-outs, such as forward-looking exclusions for all orphan drugs, which may render the agreements less impactful than the administration claims.
